Biogen Moves Into Neuropsychiatry With Pfizer AMPA Receptor Modulator
The Phase IIb-ready, glutamate-modulating candidate shelved by Pfizer after a portfolio review will help Biogen offset the risk posed by its Phase III Alzheimer's candidate aducanumab.
You may also be interested in...
The investment community has been willing Biogen to make a big deal for some time now but a modest pact inked with Japan's TMS for its Phase II acute ischemic stroke drug suggests that management will continue to favor picking up promising compounds rather than diving into major M&A.
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
Antibody was approved in the US with a liver safety warning while EU regulators recently limited the drug's use. Now, EMA has begun an urgent review of reports of inflammatory brain disorders related to Zinbryta.